Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a phase II study evaluating the efficacy of lenvatinib plus pembrolizumab in the treatment of progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) and recurrent/metastatic non-ACC salivary gland cancers (R/M SGC). Patients will be enrolled in two cohorts: Cohort 1, patients with R/M ACC ("ACC group"), and Cohort 2: patients with R/M SGC ("non-ACC group").Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04209660
- Collaborators
- Merck Sharp & Dohme Corp.
- Eisai Inc.
- Investigators
- Principal Investigator: Alan Ho, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon